Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From ChromaDex, Inc.
ChromaDex trims loss, adds Nestle as Niagen customer; currency exchange slams Mannatech; Asia-Pacific sales, currency exchange Rock USANA results; and Lannett sees upsides after 25% sales slide.
In response to what it says was unexpected airing of ChromaDex' ongoing disputes with Elysium Health, CRN will require speakers at its events to submit materials its review. Chromadex says CRN asked for the type of presentation its chairman made while Elysium Health wasn’t surprised a ChromaDex executive would comment on the litigation.
Marking Coty’s fourth CEO appointment in less than four years, current chairman Peter Harf will lead the firm’s newly created executive committee, which also includes Coty’s CFO and Gordon von Bretten, announced on 28 May as Coty’s first-ever chief transformation officer. Von Bretten joins Coty from investment firm KKR, which is buying Coty’s professional beauty and retail hair-care businesses.
In its third-quarter earnings call, Coty leadership discussed promising “green shoots” and the firm’s highly focused strategic priorities in the shadow of the COVID-19 pandemic.
- Contract Research, Toxicology Testing-CRO
- Consulting Services
- OTC, Consumer
Drug Discovery Tools
- Natural Products
- Molecular Diversity
- Drug Discovery Tools
- Other Names / Subsidiaries
- Healthspan Research, LLC, ChromaPharma Inc, ChromaDex Corp.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.